{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:39:40Z","timestamp":1787510380941,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Treatment of COVID-19 with a soluble version of ACE2 that binds to SARS-CoV-2 virions before they enter host cells is a promising approach, however it needs to be optimized and adapted to emerging viral variants. The computational workflow presented here consists of molecular dynamics simulations for spike RBD-hACE2 binding affinity assessments of multiple spike RBD\/hACE2 variants and a novel convolutional neural network architecture working on pairs of voxelized force-fields for efficient search-space reduction. We identified hACE2-Fc K31W and multi-mutation variants as high-affinity candidates, which we validated in vitro with virus neutralization assays. We evaluated binding affinities of these ACE2 variants with the RBDs of Omicron BA.3, Omicron BA.4\/BA.5, and Omicron BA.2.75 in silico. In addition, candidates produced in\n                    <jats:italic>Nicotiana benthamiana<\/jats:italic>\n                    , an expression organism for potential large-scale production, showed a 4.6-fold reduction in half-maximal inhibitory concentration (IC\n                    <jats:sub>50<\/jats:sub>\n                    ) compared with the same variant produced in CHO cells and an almost six-fold IC\n                    <jats:sub>50<\/jats:sub>\n                    reduction compared with wild-type hACE2-Fc.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-27636-x","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T08:02:41Z","timestamp":1673683361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulations"],"prefix":"10.1038","volume":"13","author":[{"given":"Katharina","family":"K\u00f6chl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Schopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedat","family":"Durmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Parigger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krassnigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cespugli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Welson Wen-Shang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Selluski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiehan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Zatloukal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Steinkellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian C.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"27636_CR1","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"N. Engl. J. Med."},{"key":"27636_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470\u2013473 (2020).","journal-title":"Lancet"},{"key":"27636_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"27636_CR4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","volume":"24","author":"S Su","year":"2016","unstructured":"Su, S. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 24, 490\u2013502 (2016).","journal-title":"Trends Microbiol."},{"key":"27636_CR5","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1038\/s41467-021-24435-8","volume":"12","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat. Commun. 12, 4196 (2021).","journal-title":"Nat. Commun."},{"key":"27636_CR6","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","volume":"184","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384-2393.e12 (2021).","journal-title":"Cell"},{"key":"27636_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2022","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671\u2013675 (2022).","journal-title":"Nature"},{"key":"27636_CR8","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433 (2022).","journal-title":"Cell"},{"key":"27636_CR9","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. U. S. A. 117, 11727\u201311734 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"27636_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271-280.e8 (2020).","journal-title":"Cell"},{"key":"27636_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00653-w","volume":"6","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Sig. Transduct. Target Ther. 6, 1\u201319 (2021).","journal-title":"Sig. Transduct. Target Ther."},{"key":"27636_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"27636_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905-913.e7 (2020).","journal-title":"Cell"},{"key":"27636_CR14","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41467-021-24013-y","volume":"12","author":"Y Higuchi","year":"2021","unstructured":"Higuchi, Y. et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat. Commun. 12, 3802 (2021).","journal-title":"Nat. Commun."},{"key":"27636_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","volume":"52","author":"M Haschke","year":"2013","unstructured":"Haschke, M. et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52, 783\u2013792 (2013).","journal-title":"Clin. Pharmacokinet."},{"key":"27636_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448 (2020).","journal-title":"Science"},{"key":"27636_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"27636_CR18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1126\/science.abc0870","volume":"369","author":"KK Chan","year":"2020","unstructured":"Chan, K. K. et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science 369, 1261\u20131265 (2020).","journal-title":"Science"},{"key":"27636_CR19","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"27636_CR20","doi-asserted-by":"publisher","first-page":"28046","DOI":"10.1073\/pnas.2016093117","volume":"117","author":"A Glasgow","year":"2020","unstructured":"Glasgow, A. et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc. Natl. Acad. Sci. U. S. A. 117, 28046\u201328055 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"27636_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.kint.2018.01.029","volume":"94","author":"P Liu","year":"2018","unstructured":"Liu, P. et al. Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int. 94, 114\u2013125 (2018).","journal-title":"Kidney Int."},{"key":"27636_CR22","doi-asserted-by":"publisher","first-page":"e12828","DOI":"10.15252\/emmm.202012828","volume":"13","author":"K-Y Huang","year":"2021","unstructured":"Huang, K.-Y. et al. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection. EMBO Mol. Med. 13, e12828 (2021).","journal-title":"EMBO Mol. Med."},{"key":"27636_CR23","doi-asserted-by":"publisher","first-page":"12740","DOI":"10.1038\/s41598-021-91809-9","volume":"11","author":"S Tanaka","year":"2021","unstructured":"Tanaka, S. et al. An ACE2 triple decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. Sci. Rep. 11, 12740 (2021).","journal-title":"Sci. Rep."},{"key":"27636_CR24","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.abe0075","volume":"370","author":"TW Linsky","year":"2020","unstructured":"Linsky, T. W. et al. De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science 370, 1208\u20131214 (2020).","journal-title":"Science"},{"key":"27636_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41392-021-00756-4","volume":"6","author":"F Ye","year":"2021","unstructured":"Ye, F. et al. S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. Signal Transduct. Target Ther. 6, 343 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"27636_CR26","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.csbj.2021.05.016","volume":"19","author":"L Di Rienzo","year":"2021","unstructured":"Di Rienzo, L. et al. Computational optimization of angiotensin-converting enzyme 2 for SARS-CoV-2 spike molecular recognition. Comput. Struct. Biotechnol. J. 19, 3006\u20133014 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"27636_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41589-021-00965-6","volume":"18","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants. Nat. Chem. Biol. 18, 342\u2013351 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"27636_CR28","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1021\/acs.jcim.1c00783","volume":"61","author":"B Havranek","year":"2021","unstructured":"Havranek, B., Chan, K. K., Wu, A., Procko, E. & Islam, S. M. Computationally designed ACE2 decoy receptor binds SARS-CoV-2 spike (S) protein with tight nanomolar affinity. J. Chem. Inf. Model 61, 4656\u20134669 (2021).","journal-title":"J. Chem. Inf. Model"},{"key":"27636_CR29","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1021\/acsnano.0c02857","volume":"14","author":"Y Han","year":"2020","unstructured":"Han, Y. & Kr\u00e1l, P. Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano 14, 5143\u20135147 (2020).","journal-title":"ACS Nano"},{"key":"27636_CR30","doi-asserted-by":"publisher","first-page":"14534","DOI":"10.1038\/s41598-022-18507-y","volume":"12","author":"V Durmaz","year":"2022","unstructured":"Durmaz, V. et al. Structural bioinformatics analysis of SARS-CoV-2 variants reveals higher hACE2 receptor binding affinity for Omicron B.1.1.529 spike RBD compared to wild type reference. Sci. Rep. 12, 14534 (2022).","journal-title":"Sci. Rep."},{"key":"27636_CR31","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1126\/science.aaf6638","volume":"353","author":"GP Lomonossoff","year":"2016","unstructured":"Lomonossoff, G. P. & D\u2019Aoust, M.-A. Plant-produced biopharmaceuticals: A case of technical developments driving clinical deployment. Science 353, 1237\u20131240 (2016).","journal-title":"Science"},{"key":"27636_CR32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295-1310.e20 (2020).","journal-title":"Cell"},{"key":"27636_CR33","doi-asserted-by":"publisher","first-page":"10628","DOI":"10.1128\/JVI.78.19.10628-10635.2004","volume":"78","author":"MJ Moore","year":"2004","unstructured":"Moore, M. J. et al. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J. Virol. 78, 10628\u201310635 (2004).","journal-title":"J. Virol."},{"key":"27636_CR34","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon, C. J. et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol Chem. 295, 6785\u20136797 (2020).","journal-title":"J. Biol Chem."},{"key":"27636_CR35","doi-asserted-by":"publisher","first-page":"108630","DOI":"10.1016\/j.celrep.2020.108630","volume":"34","author":"SM-C Gobeil","year":"2021","unstructured":"Gobeil, S.M.-C. et al. D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1\/S2 junction. Cell Rep. 34, 108630 (2021).","journal-title":"Cell Rep."},{"key":"27636_CR36","doi-asserted-by":"publisher","first-page":"2000566","DOI":"10.1002\/biot.202000566","volume":"16","author":"A Castilho","year":"2021","unstructured":"Castilho, A. et al. Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana. Biotechnol. J. 16, 2000566 (2021).","journal-title":"Biotechnol. J."},{"key":"27636_CR37","doi-asserted-by":"publisher","first-page":"e73641","DOI":"10.7554\/eLife.73641","volume":"10","author":"T Capraz","year":"2021","unstructured":"Capraz, T. et al. Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. Elife 10, e73641 (2021).","journal-title":"Elife"},{"key":"27636_CR38","doi-asserted-by":"crossref","unstructured":"Mamedov, T. et al. Soluble human angiotensin- converting enzyme 2 as a potential therapeutic tool for COVID-19 is produced at high levels in nicotiana benthamiana plant with potent anti-SARS-CoV-2 activity. Front. Plant Sci. 12 (2021).","DOI":"10.3389\/fpls.2021.742875"},{"key":"27636_CR39","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier, J. A. et al. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11, 3696\u20133713 (2015).","journal-title":"J. Chem. Theory Comput."},{"key":"27636_CR40","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jcc.23899","volume":"36","author":"E Krieger","year":"2015","unstructured":"Krieger, E. & Vriend, G. New ways to boost molecular dynamics simulations. J. Comput. Chem. 36, 996\u20131007 (2015).","journal-title":"J. Comput. Chem."},{"key":"27636_CR41","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/jcc.10128","volume":"23","author":"A Jakalian","year":"2002","unstructured":"Jakalian, A., Jack, D. B. & Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J. Comput. Chem. 23, 1623\u20131641 (2002).","journal-title":"J. Comput. Chem."},{"key":"27636_CR42","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants (2022)."},{"key":"27636_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","volume":"5","author":"MA Ramakrishnan","year":"2016","unstructured":"Ramakrishnan, M. A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 5, 85\u201386 (2016).","journal-title":"World J. Virol."},{"key":"27636_CR44","doi-asserted-by":"publisher","first-page":"153970","DOI":"10.1016\/j.phymed.2022.153970","volume":"98","author":"E Kicker","year":"2022","unstructured":"Kicker, E. et al. SARS-CoV-2 neutralizing activity of polyphenols in a special green tea extract preparation. Phytomedicine 98, 153970 (2022).","journal-title":"Phytomedicine"},{"key":"27636_CR45","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s41564-021-00954-4","volume":"6","author":"J Zahradn\u00edk","year":"2021","unstructured":"Zahradn\u00edk, J. et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat. Microbiol. 6, 1188\u20131198 (2021).","journal-title":"Nat. Microbiol."},{"key":"27636_CR46","doi-asserted-by":"publisher","first-page":"30494","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","volume":"22","author":"Y Shu","year":"2017","unstructured":"Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Eurosurveillance 22, 30494 (2017).","journal-title":"Eurosurveillance"},{"key":"27636_CR47","unstructured":"Gruber, K., Steinkellner, G. & Gruber, C. Determining Novel Enzymatic Functionalities Using Three-Dimensional Point Clouds Representing Physico Chemical Properties of Protein Cavities. WO2014080005A1 (2020)."},{"key":"27636_CR48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/prot.10104","volume":"47","author":"E Krieger","year":"2002","unstructured":"Krieger, E., Koraimann, G. & Vriend, G. Increasing the precision of comparative models with YASARA NOVA\u2013a self-parameterizing force field. Proteins 47, 393\u2013402 (2002).","journal-title":"Proteins"},{"key":"27636_CR49","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27636-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T09:04:36Z","timestamp":1673687076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27636-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["27636"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-27636-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1971184\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]},"assertion":[{"value":"17 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.K., T.S., V.D., L.P., A.S., A.K., M.C. report working for Innophore. W.W., X.Y., Y.Z., W.W.-S.W., C.S., T.Z., X.Z., C.B., L.L., Y.H., Z.X., Z.Z. and J.Y. report working for SignalChem Lifesciences Corporation. K.G., G.S., C.C.G. report being shareholders of Innophore, an enzyme and drug discovery company. C.B., Y.H., Z.X., Z.Z. and J.Y. report being shareholders of SignalChem Lifesciences Corporation. Additionally, G.S. and C.C.G. report being managing directors of Innophore. K.Z. reports being shareholder of Zatloukal Innovations GmbH, a company dedicated to the development of plant based biopharmaceuticals. The research described here is scientifically and financially independent of the efforts in any of the above mentioned companies and open-science.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"774"}}